%{{tag.tag}} {{articledata.title}} {{moment(articledata.cdate)}} @{{articledata.company.replace(" ","")}} comment A New Jersey-based %Biotech company is turning heads Tuesday morning after the company announced the signing an exclusive option agreement with %DanaFarberCancerInstitute to license technology targeting the MUC1-C oncoprotein. This sent shares of %HillstreamBioPharma ($HILS ) soaring during premarket trade on Tuesday as shares are currently bid up at $1.32/share (+96.72% implied open for sellers) at the time of writing. This move will be a strong continuation of the success this stock has had so far this year. Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting %Ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug-resistant and devastating cancers.